Clinical trials: Hormone Refractory
Hormone Refractory Prostate Cancer, Prostate Cancer
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy
This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen [PSA] levels) and who were about to start a new line of chemotherapy.
- Trial name
- IMMC-38 (NCT00133900)
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- Immunicon
Prostate Cancer Metastatic
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in…
- Trial name
- NCT01254279
- Testing
- CABAZITAXEL
- Where
- 165 sites in Australia, Austria and 27 more
- Volunteers
- 984 people
- Sponsor
- Sanofi
Prostatic Neoplasms
Phase II Study of BI 2536 in Prostate Cancer
A study to investigate the activity of BI 2536 in Prostate Cancer
- Trial name
- NCT00706498
- Testing
- BI 2536
- Where
- 6 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either…
- Trial name
- MEVPRO-1 (NCT06551324)
- Testing
- PF-06821497, Docetaxel, Enzalutamide
- Where
- 224 sites in United States, Argentina and 21 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Prostate Cancer, Cancer of Prostate
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
- Conditions
- Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
- Trial name
- NCT00257478
- Testing
- YM155
- Where
- 9 sites in United States, Netherlands and 1 more
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
- Trial name
- NCT00061126
- Testing
- ABX-EGF
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abgenix